SEARCH RESULTS FOR:
Manuel Viera
PRESIDENT, CHILEAN MINING CHAMBER (CÁMARA MINERA DE CHILE)
Manuel Viera discusses the nationalisation proposal by Chile’s Environmental Commission of the Constitutional Convention
Michael Cullen & Daniela Cuellar
MANAGING DIRECTOR – LATIN AMERICA (MC) & SENIOR CONSULTANT (DC), FTI CONSULTING
FTI Consulting analyses how evolving political risk in Chile relates to mining
Fernando Barrio
GERENTE GENERAL, TECNOMINA
Tecnomina is leveraging new technologies for the preventive maintenance of conveyor belts in mining (Spanish interview)
Ralph Heath
REGIONAL MANAGER AFRICA, WSP GOLDER MINING
"In West Africa new gold projects create demand for feasibility studies and environmental work, whereas in the Copperbelt the focus has fallen on expanding existing mines."
Mike Sieb
PRESIDENT, GETCHELL GOLD CORP.
"Our goal is to make Getchell Gold one of the most active junior explorers in Nevada."
Jean - Dominique Takis Kumbo
CEO, ENTERPRISE GENERALE DU COBALT (EGC)
"EGC was created in an effort to clean and control the entire supply chain of artisanal cobalt mining."
James Sapirstein
CHAIRMAN, PRESIDENT AND CEO, FIRST WAVE BIOPHARMA
"I believe that in the near future we will be able to effectively control the Covid virus with therapeutics."
Arda Ural
PARTNER & EY AMERICAS INDUSTRY MARKETS LEADER, HEALTH SCIENCES AND WELLNESS
"Our primary objective is to pivot to areas that our clients are focusing on, such as digitalization, ESG and supply chain management."
Abraham Drost
CEO, CLEAN AIR METALS
"Clean Air Metals realizes that the basket of metals we have at our Thunder Bay North project are on point for the direction that the world needs to go."
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
